Retatrutide Before and After: What the Clinical Data Shows
Last updated: June 2026
Retatrutide's Phase 3 TRIUMPH-1 trial showed participants lost an average of 25.0% of body weight at the highest dose (12mg) over 80 weeks, vs. 3.9% with placebo — compared with 24.2% over 48 weeks reported in the earlier Phase 2 trial.
Source note: TRIUMPH-1 is now published in NEJM (Jastreboff et al. 2026, PMID 42814954); its abstract reports a 25.0% mean weight loss at 12 mg over 80 weeks vs. 3.9% with placebo (treatment-regimen estimand). The 48-week Phase 2 comparison (24.2%) is peer-reviewed (Jastreboff et al., NEJM 2023, PMID 37366315).
Real weight loss results from retatrutide (LY3437943) — the triple-agonist that produced a 25.0% mean body weight loss at 12 mg over 80 weeks in Phase 3 TRIUMPH-1, building on its 24.2% Phase 2 result at 48 weeks.
Code HIGHPEPTIDES takes 15% off at checkout: $68
Affiliate link: HighPeptides earns a commission on orders. Research use only. Educational content, not medical advice.
Build your own printable peptide tracker
A personalized injection log, weekly dosing schedule and dated calendar: your compounds filled in, ready to print. Free to build and preview; $5/month to unlock printing.
Retatrutide Weight Loss by Dose
Percent change in body weight at 48 weeks across all dose groups. Data from the Phase 2 trial (NCT04881760).
How Fast Does Retatrutide Work?
Percent body weight change at key timepoints (24 and 48 weeks) across dose groups. These are the reported timepoints from the Phase 2 trial.
Note: 24- and 48-week values are least-squares means from the published Phase 2 abstract (Jastreboff et al. 2023, PMID 37366315); the 4 mg and 8 mg values are combined dose groups.
What Retatrutide Results Look Like in Real Weight
Based on trial averages applied to an example starting weight of 220 lbs (100 kg). Individual results vary.
| Dose Group | % Lost at 24 wk | Weight at 24 wk | % Lost at 48 wk | Weight at 48 wk | Total lbs Lost |
|---|---|---|---|---|---|
| Placebo | −1.6% | 216.5 lbs | −2.1% | 215.4 lbs | 4.6 lbs |
| 1 mg | −7.2% | 204.2 lbs | −8.7% | 200.9 lbs | 19.1 lbs |
| 4 mg (combined) | −12.9% | 191.6 lbs | −17.1% | 182.4 lbs | 37.6 lbs |
| 8 mg | −17.3% | 181.9 lbs | −22.8% | 169.8 lbs | 50.2 lbs |
| 12 mg | −17.5% | 181.5 lbs | −24.2% | 166.8 lbs | 53.2 lbs |
Starting weight: 220 lbs (100 kg). "Weight at X wk" = 220 × (1 − % lost). These are averages; individual results vary significantly.
Retatrutide vs. Tirzepatide vs. Semaglutide
Peak weight loss across three landmark clinical trials. Different study durations (see caveat below).
Fat Loss vs. Lean Mass
The published Phase 2 and Phase 3 abstracts cited on this page do not report fat-mass vs. lean-mass breakdowns, so we do not quote a fat-to-lean ratio here.
Resistance training during weight loss can help preserve lean mass.
Most Common Adverse Events
Gastrointestinal events were the most common adverse events in the Phase 2 trial (PMID 37366315). GI events were dose-related, mostly mild to moderate, and partially mitigated with a lower starting dose (2 mg vs. 4 mg).
Retatrutide Weight Loss Timeline
The phase 2 trial reported weight change only at 24 and 48 weeks (PMID 37366315); the early phases below describe the dosing schedule, not measured week-by-week results.
Retatrutide Before and After — The Bottom Line
What We Know
- The 12 mg dose produced 24.2% mean body weight loss at 48 weeks in Phase 2; Phase 3 TRIUMPH-1 reported 25.0% mean loss at 12 mg over 80 weeks (PMID 42814954)
- Clear dose-response: higher doses produced more weight loss
- Weight was still declining at 48 weeks (the study hadn't plateaued)
- GI side effects are the most common adverse events, dose-related and mostly mild-to-moderate, and were partly reduced by a lower starting dose (PMID 37366315)
- Triple-agonist mechanism (GIP + GLP-1 + Glucagon) differentiates it from existing drugs
- Phase 3 TRIUMPH-1 has reported (25.0% mean at 12 mg over 80 weeks); the broader TRIUMPH program continues for more definitive data
What We Don't Know
- Long-term safety beyond the 80-week TRIUMPH-1 readout is still being established — the full Phase 3 package is ongoing
- What happens after discontinuation (weight regain is expected based on other GLP-1 drugs)
- Cardiovascular outcomes data (no CVOT completed yet)
- How it compares head-to-head vs tirzepatide or semaglutide
- Optimal dosing for balancing weight loss against GI side effects
- Effects in specific populations such as older adults
- FDA approval timeline: still investigational, not approved for any indication
Essential Tools for Weight Loss Tracking
Tracking your weight, body composition, and meals is critical for anyone on a weight loss journey.
Affiliate links support HighPeptides at no extra cost.
Mental Clarity, Cognition & Inflammation
Beyond fat loss, there is interest in whether retatrutide affects cognition and inflammation. Here is the receptor-level mechanism, and exactly where the evidence stops.
Cognition. In the phase 2b ELAD trial, liraglutide did not change the primary endpoint of cerebral glucose metabolism in Alzheimer's patients, but a secondary executive-function score (ADAS-Exec) favored liraglutide over placebo (Edison 2026, PMID 41326666), and in Parkinson's the Exenatide-PD trial found exenatide preserved off-medication motor function (Athauda 2017, PMID 28781108). Retatrutide adds GIP and glucagon receptor activity (GLP-1/GIP dual agonists were neuroprotective in preclinical models, PMID 29402504; no such data are cited here for glucagon receptor activity), but whether retatrutide affects cognition in people is untested: no retatrutide-specific cognition trial exists yet.
Inflammation. In preclinical models, GLP-1 / GIP dual agonists reduced neuroinflammation and oxidative stress and protected synaptic numbers and synaptic activity (Hölscher review, PMID 29402504). Systemically, retatrutide produced a least-squares mean 24.2% reduction in body weight at 48 weeks in the highest-dose (12 mg) arm of the phase 2 obesity trial (Jastreboff 2023, PMID 37366315), but that trial's abstract reports no fat-mass or inflammatory-marker results, so any anti-inflammatory effect in people is unmeasured.
Related Research & Tools
Want the Complete Protocol Guide?
Dosing schedules, interaction warnings, and cycle protocols for 20+ compounds, all in one place.
Get the Guide: $19 (normally $29) →
The GLP-1 Owner’s Manual ($19)
Research-Grade Peptides
Sold for research use only — not FDA-approved for human use, with no guarantee of identity, purity, or dose. Ask for batch-specific certificates of analysis.
Browse Swiss Chems →Affiliate links support HighPeptides at no extra cost.
Disclaimer: This page is for educational and informational purposes only. It is not medical advice. Retatrutide (LY3437943) is an investigational drug not approved by the FDA. "Before and after" data represents clinical trial averages — individual results vary significantly. Always consult with a qualified healthcare provider. Data sourced from Jastreboff et al., N Engl J Med 2026 (Phase 3 TRIUMPH-1, PMID 42814954; ClinicalTrials.gov: NCT05929066) and Jastreboff et al., N Engl J Med 2023; 389:514-526 (Phase 2; ClinicalTrials.gov: NCT04881760).
Frequently Asked Questions
What does retatrutide weight loss look like?
Phase 3 TRIUMPH-1 data shows participants on retatrutide 12mg lost an average of 25.0% of body weight over 80 weeks (vs. 3.9% with placebo; PMID 42814954), compared with 24.2% over 48 weeks reported in the earlier Phase 2 trial.
How fast do you lose weight on retatrutide?
In the Phase 2 trial, weight loss continued throughout the 48-week study period.
Is retatrutide better than semaglutide?
In separate trials, retatrutide produced larger average weight loss (25.0% at 80 weeks in Phase 3 TRIUMPH-1; 24.2% at 48 weeks in Phase 2) than semaglutide (14.9% at 68 weeks in STEP 1, PMID 33567185), but no head-to-head statistical comparison exists. However, head-to-head trials have not been conducted, and retatrutide is not yet FDA-approved.
Buyer Q&A
Answer-first buying questions. Educational purposes only. Not medical advice.
Where can I buy retatrutide?
Is Swiss Chems a legit place to source research peptides?
What should I look for in a peptide vendor?
Get the Free 2026 Peptide Protocol Stack
Twelve compounds across four pillars: metabolic, tissue repair, longevity, cognitive. Citations included, formatted to print. Sent straight to your inbox.